Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. (RRR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02222610
Recruitment Status : Completed
First Posted : August 21, 2014
Last Update Posted : February 5, 2020
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Greater Houston Retina Research

Brief Summary:
The purpose of this study is to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy

Condition or disease Intervention/treatment Phase
Radiation Retinopathy Drug: 0.5 mg ranibizumab Procedure: Targeted Retinal Photocoagulation (TRP) Phase 2

Detailed Description:
RRR is a phase II, randomized, multicenter, clinical study to assess the tolerability and efficacy of ranibizumab treatment administered in subjects with radiation retinopathy. Subjects will be randomized into one of 3 arms; IVT monthly vs. ranibizumab treatment administered IVT monthly combined with peripheral targeted photocoagulation vs. ranibizumab treatment administered IVT for three months followed by as needed treatment of ranibizumab combined with peripheral targeted photocoagulation over 48 weeks. From week 52 to week 101, all 3 treatment arms will employ a treat and extend protocol for IVT ranibizumab treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).
Actual Study Start Date : September 23, 2014
Actual Primary Completion Date : February 2019
Actual Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Cohort A

Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.

Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a "dry" macula. For a macula to be considered "dry" persistent or recurrent fluid must be resolved on SD-OCT. The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again.

Drug: 0.5 mg ranibizumab
Other Name: Lucentis

Experimental: Cohort B

Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.

Starting at week 52, subject's will enter a treat & extend regime as described in cohort A.

Drug: 0.5 mg ranibizumab
Other Name: Lucentis

Procedure: Targeted Retinal Photocoagulation (TRP)
TRP to areas of retinal ischemia

Experimental: Cohort C

Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.

Starting at week 52, subject's will enter a treat & extend regime as described in cohort A.

Drug: 0.5 mg ranibizumab
Other Name: Lucentis

Procedure: Targeted Retinal Photocoagulation (TRP)
TRP to areas of retinal ischemia




Primary Outcome Measures :
  1. Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity at 48 weeks and 104 weeks from Day 0. [ Time Frame: 104 weeks ]

Secondary Outcome Measures :
  1. The mean number of intravitreal injections required per subject per cohort. [ Time Frame: 104 weeks ]
  2. Percentage of subjects with persistent macular edema, based on Spectral Domain Optical Coherence Tomography (SD-OCT), at 48 weeks and 104 weeks. [ Time Frame: 104 weeks ]
  3. Percentage of subjects avoiding the development of neovascular glaucoma and/or vitreous hemorrhage. [ Time Frame: 104 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Subjects will be eligible to participate if the following criteria are met:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age > 18 years
  • Active radiation retinopathy resulting from any form of radiation treatment performed within the last 3 years. Radiation retinopathy is defined as any of the following: retinal hemorrhages, exudates, edema, and/or neovascularization, not attributable to other causes.
  • Best Corrected Visual Acuity (BCVA) of 20/25-20/400 in the study eye

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from this study:

  • Pregnancy (verified by positive pregnancy test) or lactation
  • Premenopausal women not using adequate methods of contraception. The following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch.
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
  • Participation in any other simultaneous medical investigation or trial
  • Previous participation in any studies involving investigational drugs within 30 days before Day 0 (excluding vitamins and minerals).
  • History of allergy fluorescein, not amenable to treatment
  • Previous intravitreal treatment with any anti-vascular endothelial growth factor (VEGF) drug within 60 days of Day 0
  • Previous intravitreal or subconjunctival treatment with cortical steroids within 90 days of Day 0
  • History of vitrectomy
  • History of treatment with more than one form of radiation to the eye (e.g. proton beam therapy and plaque therapy).
  • Subjects who have more than 7 disc diameters of ischemia in the central macula that would hinder visual acuity improvement
  • History of panretinal photocoagulation treatment in the study eye.
  • Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analyzed
  • Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could:

    • Require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition.
    • Contribute to loss of at least 2 Snellen equivalent lines of BCVA over the 12-month study period, if allowed to progress untreated.
  • Active intraocular inflammation (grade 2+ or above) in the study eye
  • Current vitreous hemorrhage in the study eye
  • History of rhegmatogenous retinal detachment or macular hole (stage 3 or 4) in the study eye.
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
  • Aphakia or absence of the posterior capsule in the study eye.
  • Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Day 0.
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) > 30 mmHg despite treatment with anti-glaucoma medication).
  • History of glaucoma-filtering surgery in the study eye
  • History of corneal transplant in the study eye
  • Uncontrolled blood pressure (defined as systolic and/or diastolic > 180/110 mmHg while subject is seated). If the subject's initial reading exceeds these values, a second reading may be taken at least 30 minutes later. If the subject requires antihypertensive medication, the subject can become eligible if medication is taken continuously for at least 14 days prior to Day 0 and blood pressure is less that 180/110 mmHg.
  • New diagnosis of atrial fibrillation not managed by subject's primary care physician or cardiologist within 3 months of Day 0.
  • History of stroke within the last 3 months of Day 0.
  • History of myocardial infarction within 3 months of Day 0.
  • History of other disease, metabolic dysfunction, or physical examination finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or renders the subject at high risk for treatment complications.
  • Current treatment for active systemic infection
  • Active malignancy other than uveal melanoma
  • Presence of metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02222610


Locations
Layout table for location information
United States, Texas
Texas Retina Associates
Dallas, Texas, United States, 75231
Retina Consultants of Houston/The Medical Center
Houston, Texas, United States, 77030
Retina Consultants of Houston
Katy, Texas, United States, 77494
Retina Consultants of Houston
The Woodlands, Texas, United States, 77384
Sponsors and Collaborators
Greater Houston Retina Research
Genentech, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Amy C Schefler, MD Retina Consultants Houston
Publications:

Layout table for additonal information
Responsible Party: Greater Houston Retina Research
ClinicalTrials.gov Identifier: NCT02222610    
Other Study ID Numbers: ML29236
First Posted: August 21, 2014    Key Record Dates
Last Update Posted: February 5, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Greater Houston Retina Research:
Radiation Retinopathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinal Diseases
Eye Diseases
Ranibizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents